India, Nov. 2 -- Seaport Therapeutics, Inc. (SPTX) reported third-quarter 2026 financial results and highlighted clinical progress across its neuropsychiatric pipeline. The company announced positive Phase 1 driving simulation results for GlyphAllo and initiated a Phase 2a trial of GlyphAgo in generalized anxiety disorder (GAD).
Company Profile
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing oral treatments for depression, anxiety and other neuropsychiatric disorders using its proprietary Glyph platform.
Third Quarter 2026 Financial Highlights
Research and development expenses increased to $23.9 million from $20.5 million in the prior-year quarter, primarily due to higher clinical development costs for Glyp...